Health experts are examining the safety of peptides, substances gaining popularity in wellness circles without solid supporting evidence. The FDA, with Health Secretary Robert F. Kennedy Jr.’s endorsement, is holding a two-day meeting to discuss these compounds.
Support for peptides comes from figures like Joe Rogan and Gary Brecka, who tout their benefits for muscle gain, injury recovery, and anti-aging. Despite their popularity, the FDA has highlighted risks associated with peptides.
FDA scientists argue there’s insufficient data to permit broader distribution through compounding pharmacies. Many medical professionals share this view, citing a lack of clinical evidence.
The advisory panel reviewing peptides includes several members linked to the industry, raising concerns about conflicts of interest. This panel consists of owners of wellness clinics and pharmacies involved with peptides.
The FDA recently added non-industry experts to the 20-member panel. The scientific consensus remains wary of peptide safety and efficacy.
Panel experts will vote on seven peptides for compounding pharmacy safety. These votes are advisory, not decisive, as the FDA sometimes ignores panel recommendations.
Peptides are integral to various bodily functions like growth and metabolism. Pharmaceutical companies have used them for medications, targeting conditions like diabetes.
The FDA cites risks with peptides such as BPC-157 and TB-500, involved in sports doping and inflammation treatment. Their safety remains uncertain, with limited data derived from animal studies rather than human trials.
Public interest is high, with over 1,900 comments received by the FDA prior to the meeting. Some argue for safe and legal peptide access, advocating for regulated pharmacy distribution.
After discussions, the FDA will decide on regulatory changes, which could take significant time. A temporary measure may reassure pharmacies compounding these peptides won’t face immediate scrutiny.
Ultimately, the outcome may align with Secretary Kennedy’s aims, influencing future peptide regulations.
The AP Health and Science Department notes their coverage is supported by the Howard Hughes Medical Institute and the Robert Wood Johnson Foundation, although editorial decisions remain independent.